New Insights in Antibody Therapy
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".
Deadline for manuscript submissions: 30 July 2025 | Viewed by 99
Special Issue Editor
Interests: autoimmunity; basic immunology; T-cell; B-cell and dendritic cell biology; transplantation; anti-infectious immune response
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Antibody therapy is extensively employed to treat several chronic diseases, from autoimmune diseases to cancer, as well as some infectious diseases.
While antibody therapy can be utilized to cure these diseases or at least mitigate inflammation or cytokine storms, adverse events can also occur. To enhance this therapy, humanized antibodies have been developed. However, the production of antibodies by the host remains a challenge, as these antibodies block these drugs. An example of this is the well-documented use of drugs that target tumor necrosis factor alpha (TNF-alpha), a factor involved in several chronic diseases such as psoriasis and inflammatory bowel disease (IBD). Researchers have therefore endeavored to reduce the immunogenicity of these antibodies when used as a drug in order to avoid their inactivation.
This Special Issue welcomes the submission of research or review articles that address the use of these drugs in several chronic, immune-mediated and infectious diseases. It also welcomes studies that aim to improve the half-life of these drugs without increasing the incidence of side effects.
Dr. Loredana Frasca
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biological therapy
- antibody therapy
- non-communicable diseases
- infectious diseases
- chronic disease
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
